What is the most appropriate medication for short‑term insomnia in adults, considering safety and contraindications?

Best Sleep Medication for Short-Term Insomnia in Adults

For short-term insomnia in adults, use eszopiclone (2-3 mg), zolpidem (10 mg), or suvorexant (10-20 mg) as first-line pharmacologic options, with the specific choice determined by whether the primary problem is sleep onset versus sleep maintenance. These agents have the strongest evidence for efficacy with acceptable safety profiles for short-term use 1.

Medication Selection Algorithm

For Sleep Onset Insomnia (Difficulty Falling Asleep):

• First choice: Zolpidem 10 mg - effective for both sleep onset and maintenance 1
• Alternative: Zaleplon 10 mg - specifically for sleep onset only 1
• Alternative: Ramelteon 8 mg - if concerned about abuse potential, though weaker evidence 1

For Sleep Maintenance Insomnia (Frequent Awakenings, Early Morning Awakening):

• First choice: Suvorexant 10-20 mg - orexin receptor antagonist with specific efficacy for sleep maintenance 1
• Alternative: Doxepin 3-6 mg - low-dose tricyclic specifically for sleep maintenance 1

For Both Sleep Onset AND Maintenance Problems:

• First choice: Eszopiclone 2-3 mg - addresses both components 1
• Alternative: Zolpidem 10 mg - also effective for both 1

Critical Safety Considerations

Absolute contraindications and dose adjustments:

• Women and older adults require lower doses - FDA mandates dose reduction due to increased risk of next-day impairment and driving accidents 2
• Avoid in patients at high fall risk - observational data links hypnotics to increased fractures and major injury 2
• Avoid in patients with cognitive concerns - associated with increased dementia risk in long-term observational studies 2

Medications to AVOID

The American Academy of Sleep Medicine explicitly recommends AGAINST these commonly used agents 1:

• Trazodone - insufficient efficacy evidence despite widespread off-label use
• Diphenhydramine (Benadryl) - anticholinergic effects, next-day sedation, tolerance
• Melatonin - insufficient evidence for insomnia disorder (distinct from circadian rhythm disorders)
• Valerian, tryptophan - no proven efficacy

Benzodiazepines (triazolam 0.25 mg, temazepam 15 mg) have weak recommendations for use but carry higher risks of dependence, cognitive impairment, and falls compared to non-benzodiazepine options 1.

Duration and Monitoring

• Maximum duration: 4 weeks for benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) 2
• Effect sizes are modest - improvements in sleep onset latency and total sleep time are statistically significant but clinically small (10-30 minutes) 2
• Long-term efficacy unknown - most trials were short-term, and comparative effectiveness data are lacking 2

Important Caveats

All pharmacologic recommendations carry WEAK strength in the AASM guidelines 1, reflecting:

• Small effect sizes in absolute terms
• Limited long-term safety data
• Risk of cognitive/behavioral changes including driving impairment
• Potential for dependence with prolonged use

The European guideline emphasizes that cognitive behavioral therapy for insomnia (CBT-I) should be first-line treatment when available, with medications reserved for CBT-I failure or unavailability 3.

Practical Implementation

When prescribing any hypnotic:

1. Verify adequate sleep opportunity - insomnia symptoms must occur despite adequate time/environment for sleep
2. Rule out other sleep disorders - sleep apnea, restless legs syndrome, circadian rhythm disorders require different management
3. Screen for substance effects - caffeine, alcohol, medications causing insomnia
4. Assess fall risk - particularly in older adults
5. Set clear expectations - short-term use only, modest improvements expected
6. Plan discontinuation strategy - taper after 2-4 weeks to avoid withdrawal